Skip to main content

Advertisement

SpringerLink
Log in

Are we ready for an early evaluation of the response of axillary lymph node metastases to neoadjuvant therapy?

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Rousseau C, Devillers A, Campone M, Campion L, Ferrer L, Sagan C, et al. FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients. Eur J Nucl Med Mol Imaging. 2011;38:1029–36.

    Article  PubMed  CAS  Google Scholar 

  2. Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Jänicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med. 2005;46:1144–50.

    PubMed  Google Scholar 

  3. Basu S, Kwee TC, Torigian D, Saboury B, Alavi A. Suboptimal and inadequate quantification: an alarming crisis in medical application of PET. Eur J Nucl Med Mol Imaging. 2011;38:1381–2.

    Article  PubMed  Google Scholar 

  4. qqSchneider-Kolsky ME, Hart S, Fox J, Midolo P, Stuckey J, Hofman M, et al. The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET. Breast Cancer Res. 2010;12:R37.

    Article  PubMed  Google Scholar 

  5. Gilardi L, De Cicco C, Colleoni M, Cardillo A, Montagna E, Dellapasqua S, et al. Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy. Eur J Nucl Med Mol Imaging. 2010;37:1834–41.

    Article  PubMed  Google Scholar 

  6. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M, Kau SW, Broglio K, et al. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer. 2006;106(5):1000–6.

    Article  PubMed  Google Scholar 

  7. Rouzier R, Extra J-M, Klijanienko J, Falcou M-C, Asselain B, Vincent-Salomon A, et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol. 2002;20:1304–10.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nuclear Medicine, European Institute of Oncology, Milan, Italy

    Laura Gilardi, Concetta De Cicco & Giovanni Paganelli

  2. European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy

    Giovanni Paganelli

Authors
  1. Laura Gilardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Concetta De Cicco
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giovanni Paganelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Paganelli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gilardi, L., De Cicco, C. & Paganelli, G. Are we ready for an early evaluation of the response of axillary lymph node metastases to neoadjuvant therapy?. Eur J Nucl Med Mol Imaging 38, 2096–2097 (2011). https://doi.org/10.1007/s00259-011-1921-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-011-1921-y

Keywords

Search

Navigation